What amount sold does Alpheus Medical, Inc. report in Form D filings?

The latest linked filings report $82.1M sold across 6 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Alpheus Medical, Inc.'s most recent SEC filing?

Alpheus Medical, Inc.'s most recent Form D filing was on 2026-07-30.

How many investors does Alpheus Medical, Inc. have?

The most recent Form D filing lists 22 investor(s).

What type of securities does Alpheus Medical, Inc. offer?

Alpheus Medical, Inc.'s SEC Form D filings indicate equity offerings.

Alpheus Medical, Inc.

CIK: 0001716636·Biotechnology·Chanhassen, MN·Corporation

Reported Sold

$82,136,409

Total Filings

Identified Offerings

Last Filed

Jul 30, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Other industry

SEC EDGAR

Offering filing timeline

Jul 30, 2026Form D/A — Amendment

Reported sold: $60,477,409 · Target: $66,977,409

Rule 506(b)·22 investors

Changed: Reported amount sold, Offering target

May 19, 2025Form D — New notice

Reported sold: $34,527,457 · Target: $60,477,409

Rule 506(b)·22 investors

Nov 9, 2022Form D — New notice

Reported sold: $13,999,995 · Target: $13,999,995

Rule 506(b)·4 investors

Dec 23, 2020Form D — New notice

Reported sold: $6,000,000 · Target: $16,000,000

Rule 506(b)·23 investors

May 1, 2020Form D/A — Amendment

Reported sold: $519,000 · Target: $700,000

No verified predecessor available.

Rule 506(b)·12 investors

Oct 29, 2018Form D/A — Amendment

Reported sold: $1,284,005 · Target: $1,300,000

Rule 506(b)·22 investors

Changed: Reported amount sold, Offering target, Reported investors

May 2, 2018Form D — New notice

Reported sold: $642,873 · Target: $1,000,000

Rule 506(b)·5 investors

Mar 28, 2018Form D/A — Amendment

Reported sold: $150,000 · Target: $150,000

Rule 506(b)·2 investors

Changed: Reported amount sold, Reported investors

Jan 25, 2018Form D — New notice

Reported sold: $100,000 · Target: $150,000

Rule 506(b)·1 investor

Sep 11, 2017Form D — New notice

Reported sold: $225,000 · Target: $300,000

Rule 506(b)·2 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$301,923

Amendment Rate

40%

Latest reported sold across 6 identified offerings

$82,136,409

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

William Davis

Related Person

Appears on 2 filings

Vijay Agarwal

Related Person

Appears on 2 filings

Vijay Agarwal

Related Person

Appears on 2 filings

Vijay Agarwal

Related Person

Appears on 2 filings

Imran Eba

Related Person

Appears on 2 filings

Peter Thompson

Related Person

Appears on 2 filings

Klaus Veitinger

Related Person

Appears on 2 filings

William Davis

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 30, 2026	Amendment	$66,977,409	$60,477,409	22
May 19, 2025	New	$60,477,409	$34,527,457	22
Nov 9, 2022	New	$13,999,995	$13,999,995	4
Dec 23, 2020	New	$16,000,000	$6,000,000	23
May 1, 2020	Amendment	$700,000	$519,000	12
Oct 29, 2018	Amendment	$1,300,000	$1,284,005	22
May 2, 2018	New	$1,000,000	$642,873	5
Mar 28, 2018	Amendment	$150,000	$150,000	2
Jan 25, 2018	New	$150,000	$100,000	1
Sep 11, 2017	New	$300,000	$225,000	2

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Elucid Bioimaging Inc.

Biotechnology

Offering target: $79,999,999

Filed Oct 27, 2026